009290 fundamentals
KWANGDONG PHARMACEUTICAL financial statements, including revenue, expenses, and profit
The total revenue of 009290 for the last quarter is 390.83 B KRW, and it's 7.95% lower compared to the previous quarter. The net income of Q4 24 is 12.14 B KRW.
Q1 '17
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
0.00
110.00 B
220.00 B
330.00 B
440.00 B
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: KRW
Q1 '17
Mar 2017
Q2 '17
Jun 2017
Q3 '17
Sep 2017
Q4 '17
Dec 2017
Q1 '18
Mar 2018
Q2 '18
Jun 2018
Q3 '18
Sep 2018
Q4 '18
Dec 2018
Q1 '19
Mar 2019
Q2 '19
Jun 2019
Q3 '19
Sep 2019
Q4 '19
Dec 2019
Q1 '20
Mar 2020
Q2 '20
Jun 2020
Q3 '20
Sep 2020
Q4 '20
Dec 2020
Q1 '21
Mar 2021
Q2 '21
Jun 2021
Q3 '21
Sep 2021
Q4 '21
Dec 2021
Q1 '22
Mar 2022
Q2 '22
Jun 2022
Q3 '22
Sep 2022
Q4 '22
Dec 2022
Q1 '23
Mar 2023
Q2 '23
Jun 2023
Q3 '23
Sep 2023
Q4 '23
Dec 2023
Q1 '24
Mar 2024
Q2 '24
Jun 2024
Q3 '24
Sep 2024
Q4 '24
Dec 2024
TTM
Total revenueYoY growth
356.95 B
+14.32%
375.36 B
+3.74%
397.84 B
+5.35%
384.31 B
+1.18%
412.49 B
+15.56%
412.81 B
+9.98%
424.59 B
+6.72%
390.83 B
+1.70%
1.64 T
−283.74 B
−298.14 B
−320.12 B
−313.57 B
−334.03 B
−339.07 B
−354.09 B
−320.28 B
−1.35 T
Gross profitYoY growth
73.21 B
+18.38%
77.22 B
+9.71%
77.71 B
+3.95%
70.74 B
−3.22%
78.45 B
+7.16%
73.74 B
−4.51%
70.50 B
−9.28%
70.55 B
−0.27%
293.25 B
−57.40 B
−65.30 B
−66.62 B
−66.69 B
−61.42 B
−68.70 B
−69.13 B
−63.90 B
−263.15 B
Operating incomeYoY growth
15.81 B
+76.76%
11.93 B
+16.06%
11.09 B
+44.62%
4.05 B
−63.93%
17.03 B
+7.68%
5.04 B
−57.73%
1.37 B
−87.63%
6.65 B
+64.15%
30.10 B
−1.96 B
1.08 B
−525.66 M
6.22 B
8.70 B
−2.38 B
10.55 B
7.35 B
24.22 B
Pretax incomeYoY growth
13.86 B
+24.66%
13.01 B
+147.85%
10.56 B
+8.30%
10.27 B
−4.11%
25.73 B
+85.69%
2.67 B
−79.52%
11.92 B
+12.81%
14.00 B
+36.35%
54.31 B
−269.27 M
−174.06 M
576.76 M
1.19 B
−106.84 M
−90.93 M
33.65 M
3.18 B
3.01 B
1.38 B
−3.84 B
−1.82 B
−5.37 B
−7.26 B
−876.39 M
−3.00 B
−4.34 B
−15.48 B
−920.92 M
−443.35 M
−488.99 M
−552.94 M
−159.74 M
−374.50 M
−137.33 M
−692.41 M
−1.36 B
14.04 B
8.56 B
8.83 B
5.53 B
18.20 B
1.32 B
8.82 B
12.14 B
40.48 B
Net incomeYoY growth
14.04 B
+85.11%
8.56 B
+185.24%
8.83 B
+37.10%
5.53 B
−22.57%
18.20 B
+29.59%
1.32 B
−84.54%
8.82 B
−0.16%
12.14 B
+119.42%
40.48 B
14.04 B
8.56 B
8.83 B
5.53 B
18.20 B
1.32 B
8.82 B
12.14 B
40.48 B
Basic earnings per share (Basic EPS)YoY growth
341.87
+85.11%
210.48
+188.21%
220.32
+40.52%
138.05
−20.64%
454.09
+32.82%
33.01
−84.31%
219.97
−0.16%
304.27
+120.40%
1.01 K
Diluted earnings per share (Diluted EPS)YoY growth
341.87
+85.11%
210.48
+188.21%
220.32
+40.52%
138.05
−20.64%
454.09
+32.82%
33.01
−84.31%
219.97
−0.16%
304.27
+120.40%
1.01 K
41.08 M
40.66 M
40.08 M
40.08 M
40.08 M
40.08 M
40.08 M
39.90 M
—
41.08 M
40.66 M
40.08 M
40.08 M
40.08 M
40.08 M
40.08 M
39.90 M
—
EBITDAYoY growth
19.02 B
+52.33%
15.06 B
+8.64%
14.68 B
+31.05%
6.96 B
−52.09%
20.84 B
+9.60%
8.46 B
−43.81%
4.74 B
−67.75%
10.46 B
+50.39%
44.51 B
EBITYoY growth
15.81 B
+76.76%
11.93 B
+16.06%
11.09 B
+44.62%
4.05 B
−63.93%
17.03 B
+7.68%
5.04 B
−57.73%
1.37 B
−87.63%
6.65 B
+64.15%
30.10 B
−341.13 B
−363.43 B
−386.74 B
−380.26 B
−395.46 B
−407.77 B
−423.22 B
−384.18 B
−1.61 T